fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

AI Euphoria Propels NASDAQ Megas Higher Despite Debt Ceiling & Inflation Worries – $AAPL $AI $ATOS $META $MRVL $NVDA $TSLA Rise!

By John F. Heerdink, Jr.
LinkedIn Twitter Disclaimer


Quote of the Day:  “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain


Happy Memorial Day Weekend!

I hope that you have experienced continued success this week and found many ways to increase wealth and happiness. 

As for the broad markets this week, stocks danced around on the top end of the market along with the ebbs and flows of the ongoing US debt ceiling issues that continued to haunt us as our crack team of politicians play there games and extend the so-called ‘negotitations. Going into the long weekend new were led to believe that they were making ‘progress’ and U.S. Treasury Secretary Janet Yellen stated that she now sees an extended deadline for raising the federal debt limit, confirming  the government would now be in a position to default if Congress does not increase the ceiling to $31.4T by June 5, not June 1 as she originally and alarming had claimed. The CBOE Volatility Index (^VIX) closed at $7.95 moving up another 4.30% this week as tensions mounted. However, on the bank front, The SPDR S&P Regional Banking ETF (KRE) rose another 2.75% this week to close at $40.29 & the SPDR S&P Bank ETF (KBE) rose 1.66% over the last 5-days to close at $35.01 as worries subsided to some degree.  

A number of macroeconomic reports also surfaced once again this week, which supported overall a belief that the Fed will raise rates again when they meet again in June. On Tuesday, the preliminary IHS Markit Manufacturing PMI report for May confirmed a drop to 48.5. The preliminary May IHS Markit Services PMI report also showed a rise to 55.1. The New home sales report also showed a 4.1% M/M rise in April to land it at a seasonally adjusted annual rate of 683k units, while on a Y/Y basis, new home sales have jumped 11.8%. On Wednesday, the weekly MBA Mortgage Application Index report, which showed a 4.6% decline while purchase applications fell in concert by 4% & refinance applications fell even further by 5%.
The weekly EIA Crude Oil Inventories report confirmed a 12.46M barrel draw. On Thursday, the 2nd estimate for Q1 GDP was moved higher to 1.3% & the GDP Price Deflator was also moved up to 4.2%. The Initial claims report for the week ending May 20 confirmed a rise by 4k to 229k & the continuing jobless claims report for the week ending May 13 fell by 5k to 1.794M. On Friday, the Personal income report showed a rise by .4% M/M in April. The Personal spending report showed a .8% M/M rise. The PCE Price Index report confirmed a .4% M/M increase & is now up up 4.4% Y/Y. The core-PCE Price Index was confined to be up .4%. The Durable goods orders report showed a 1.1% M/M rise in April. The Advance International Trade in Goods Report for April confirmed a widening in the deficit to $96.8B. The final University of Michigan Consumer Sentiment Index for May clocked in higher at 59.2. Oil prices rose 1.14% to close at $72.87/bbl and is down 5.35% YTD. As a result, the yield curve rose significantly over the course of the week with 2-yr note yield moving 29 bps to 4.56% & the 10-yr note yield moved up 14bps to 3.80%. The U.S. Dollar Index moved up from 103.19 to close the week at 104.23.

The S&P 500 closed at 4,205.45 (-1%) for the week and is now up 9.2% YTD. 8 of the 11 sector fell this week as the information technology sector logged the biggest gain for the second consecutive week up 5.1% & the communication services moved up another 1.3% (nearly 10% into 2-wks), & the consumer discretionary ticked up ,4%. The consumer staples sector chunked down a solid 3.2% followed by a 3.1% drop in the materials sector. The 6.82% weighting of the shares of mega cap Apple (AAPL) closed at $175.43, +.15% over the last 5-days. EV giant Tesla (TSLA) closed at $193.17 jumping 7.23% over the course of the week and is not up +14% over the last two weeks.  

The Dow 30 closed at 33,093.30 (-1.0%) and is now down .2% YTD.  The Walt Disney Company (DIS) closed at $91.30, -.79% over the last 5-days as the company stated that they are scrapping theirs plans for new Florida campus amid their feud with Gov. DeSantis and therefore remaining in California. Nike (NKE) closed at $114.76, -4.53% over the last 5-days. This week, according to the blog ClassAction.org citing the 47-page lawsuit, Nike has illegally attempted to capitalize on consumers’ preference for “green” products by falsely claiming that certain apparel is tagged with “sustainable” claims.

The Nasdaq closed at 12,975.60 (+2.5%) and now up 24% YTD. Meta Platforms, Inc. (META) rose 6.68% this week to close at $262.04. However, NVIDIA (NVDA) stole the show this week jumping 24.57% (nearly at a $1Trillion Mkt cap) as they beat the street’s estimates and Jensen Huang, founder and CEO stated, “The computer industry is going through two simultaneous transitions — accelerated computing and generative AI,” said Jensen Huang, founder and CEO of NVIDIA. A trillion dollars of installed global data center infrastructure will transition from general purpose to accelerated computing as companies race to apply generative AI into every product, service and business process. Our entire data center family of products — H100, Grace CPU, Grace Hopper Superchip, NVLink, Quantum 400 InfiniBand and BlueField-3 DPU — is in production. We are significantly increasing our supply to meet surging demand for them.” Marvell Technology (MRVL) also jumped a whopping 44.10% over the week as they beat the street too and named AI a ‘key growth driver’. C3.ai, Inc. (AI) also jumped a cool 30,30% this week to close at $32.94.

The small caps on the Russell 2000 closed at 1,773.02 (-o.o%) for the week & is now down .7% YTD. The MicroCaps also moved solidly higher again this week as the iShares Micro-Cap ETF (IWC) closed at $103.90,-.54% this week & remains down 3.64% YTD.  

On the larger side of things, the Nasdaq Biotechnology ETF (IBB) closed at $127.09, -2.30% over the last 5-days and is -3.20% YTD, the NYSE ARCA Biotech Index (^BTK) closed at 5,291.77, -2.31% over the last 5-days and is now +.20% YTD, & the the lower side of the biotech market the SPDR S&P Biotech ETF (XBI) closed at $84.31, down 1.24% over the last 5-days, & is +1.58% YTD. The 52-week range is is now $61.78-$95.18.  

The iShares U.S. Healthcare ETF (IYH) closed at $269.07, -.2.76% over the last 5-days and is now down 2.46% YTD.  

From the world of cryptocurrency, Bitcoin (BTC) moved down to $26,752.33 & down .37% over the course of the last 5-days at the time of the completion of this message. 

Gold prices closed at $1946.10 off 1.57% over the last 5-days. Silver prices closed at $23.45 off 1.74% over the last 5-days. 

VP Watchlist Updates


This week, our sister organization Tribe Public co-hosted three CEO Presentation and Q&A events in the greater Phoenix area with Panna Sharma, CEO of Lantern Pharma (NASDAQ: LTRN, $4.84), an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Their proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, they have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, their newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.

Panna Sharma Lantern’s CEO and President stated recently, “This quarter we continued to execute our mission of transforming the oncology drug discovery and development process using our industry-leading AI platform RADR®. We are deploying AI at a massive scale – think millions of simultaneous instances of competing and synergistic algorithms – to determine drug and cancer correlations that would be far too complex and time-consuming for any team of humans to fully analyze, let alone replicate. AI is enabling us to understand and predict drug-cancer interactions, create new drug programs, and discover cancer biology insights at a cost and timeline that was unimaginable in the near past, and Lantern Pharma is at the forefront of this transformative approach.” 

Learn more about Lantern at their website https://www.lanternpharma.com. 



The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. INVO Bioscience, Inc. (NASDAQ: INVO) offers the INVOcell solution which provides an advanced, effective and affordable infertility treatment to help increase access to care. INVO is commercially advancing INVOcell through the opening of INVO Centers, opportunistically now pursuing acquisitions of established fertility (IVF) clinics in the U.S., and continuing to offer the technology to existing fertility practices.  Shares INVO closed at $.3001. The 52-wk range is $.31 – $1.65.

On May 15, INVO announced financial results for the quarter ended March 31, 2023 and provided a business update. Steve Shum, CEO of INVO stated, “We made significant progress on nearly every key operational metric during the first quarter, particularly within our three existing INVO Centers in Atlanta, Birmingham and Monterrey achieving record levels of revenue and patient cycles. These three centers combined to generate $646,707 in revenue, an increase of 108% from the first quarter of the prior year and were ahead 46% sequentially from Q4 2022, as patients increasingly recognize and value the remarkable opportunity INVO offers to assist families with affordable fertility options. We are extremely pleased to see the existing clinics nearing break-even and look forward to each of them generating positive cashflows and profits in the near future. Tampa Fertility Institute, our planned INVO Center in Tampa, is progressing with a mid-summer target opening and we are also executing on the early preparation work for an INVO Center in Kansas City. To build on the success we are achieving with our INVO Centers, we expanded our commercialization approach to include the acquisition of established and profitable US IVF clinics and announced the execution of binding agreements to acquire Wisconsin Fertility Institute,” Shum continued. “We view our acquisition strategy as highly complementary to our ongoing efforts to build new INVO Centers, increase sales of our INVOcell® device and expand adoption of the IVC procedure. We expect this strategy to accelerate our corporate development efforts and our path to profitability, as we integrate IVC alongside IVF. We view these two procedures as highly complementary to each other and to our mission of expanding access and affordability for the millions of people for whom the cost of IVF is out of reach. We look forward to closing the acquisition in the current quarter.”

On April 18, Maxim Group’s Analyst Jason McCarthy, Ph.D. issued a BUY rating on INVO Bioscience (INVO), a commercial-stage fertility company focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. His report is titled, “4Q Results and Outlook: Fertility Space Remains Active as INVO Expands Strategy with IVF Clinic Acquisition.” His 12-month Price Target is $3. 


  • Borqs Technologies, Inc. (Nasdaq: BRQS, $.2222), a global provider of 5G wireless solutions, Internet of Things (IoT) solutions, and innovative clean energy, recently provided the following updates on the Company.
  • On April 26, Borqs Technologies published its Letter to Shareholders Regarding the Divestment of Solar Subsidiary. “Dear Shareholders of Borqs Technologies, Inc.: The purpose of this letter is to help clarify the proposed divestment of our company’s ownership in Holu Hou Energy, LLC (“HHE”) and the implications that this transaction may have to Borqs and our shareholders. Why the divestment? As we have stated in prior press releases, the Committee on Foreign Investment in the United States (“CFIUS”) has notified our company by a letter dated December 13, 2022, that CFIUS has identified risks to US national security arising as a result of Borqs’s investment in HHE. CFIUS advised us that the national security risks arising as a result of Borqs’s investment transaction with HHE relate to foreign proximity to U.S. military personnel and installations through HHE’s physical access to customers and their facilities, including at off-base military housing. CFIUS therefore required Borqs and HHE to enter into a National Security Agreement with CFIUS, pursuant to which Borqs must divest its interests in HHE. Proactive steps by Borqs. Read the balance here:” 
  • On April 20, Borqs announced that its subsidiary, Holu Hou Energy LLC (HHE), a provider of design-to-service solar plus energy storage systems, has signed a contract to install HHE’s HoluPower energy storage and solar photovoltaic (PV) systems on homes at Lendlease’s Island Palm Communities (IPC) in Honolulu, Hawaii. When completed, the project will be worth well into the nine figures in sales for HHE. Lendlease, a leading real estate and investment group that manages almost 8,000 homes for the U.S. Army on Oahu, is the purchaser of the electricity and the installations will come in the form of HHE’s EnergyCluster, where multiple residential units have their systems connected in an energy network or “cluster.” Excess solar generation from any unit’s system in the network that would normally be lost is directly shared in real time with other connected units that have load above solar generation. The benefit is that the optimized PV and energy storage systems can meet 75-80% or more of the overall residents’ energy needs while not exporting power to the utility grid. Lendlease and HHE began initial planning in 2021, which culminated in constructing a “pilot” project in May 2022. Since then, the pilot has been operating with outstanding results across six residential units. In a typical month, approximately a third of the total generated electricity is shared with other units in the “cluster” thereby solving issues related to vacancy and resident load variability, while proving out the superior value created through a clustered approach versus stand-alone systems. The savings realized by Island Palm Communities through deployment of HHE’s systems is being reinvested to enhance the housing and amenities Lendlease offers to military families on the installation. Additionally, residents now have resilient back-up power that can be utilized during grid outage events. These systems also take a load burden off the Oahu electric grid, which improves overall stability. Each residential unit will have approximately 10kW of PV and 25 kWh of energy storage, with six residences typically being connected in an HHE EnergyShare network. Construction is set to begin summer of 2023, with initial installations at the Aliamanu Military Reservation near Honolulu.


Shares of InMed Pharmaceuticals Inc. (INM), a leader in the research, development and manufacturing of rare cannabinoids, closed at $1.27.

  • Please join me this week for Tribe Public’s Next Webinar Presentation and Q&A Event, which will be held Wednesday, May 31, 2023 (9am PT/ 12pm ET). Eric A. Adams, MIBS, CEO & President of InMed Pharmaceuticals (NASDAQ: INM) & BayMedica’s Jerry P. Griffin, VP, Sales and Marketing will co-host a presentation and Q&A event titled “Addressing The Increasing Demand For Rare Cannabinoids”. Register for this event at INMMay25@TribePublic.com. They also will be available for a 5-10 minute Q&A session at the end of the presentation, so please send your questions for management to Tribe’s email: research@tribepublic.com.

  • Eric Adams recently stated, “In the last few months we have seen a noticeable increase in awareness, understanding and adoption of rare cannabinoids in the H&W sector, evidenced by leading companies expanding their product lines to include new formats and formulations using rare cannabinoids such as the non-psychoactive ingredient cannabichromene (“CBC”). We are encouraged by two consecutive periods of significant quarter over quarter revenue growth. We will continue to support growth in a fiscally prudent manner in this relatively nascent market, where product demand can be unpredictable. The combination of a pharmaceutical drug development pipeline, together with a revenue generating commercial operation that will be contributing to extending our cash runway makes InMed a unique company within the rare cannabinoid space.”
  • On March 28, InMed announced it has concluded enrollment of its Phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”), a rare genetic skin disease. The Phase 2 study, called INM-755-201-EB, enrolled 19 patients. All four subtypes of inherited EB, including EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome were accepted into the trial. The clinical trial is evaluating the safety of INM-755 cannabinol cream and its preliminary efficacy in treating symptoms of itch, pain, and wound healing in patients with epidermolysis bullosa. The study used a within-patient, double-blind design whereby matched index areas are randomized to INM-755 (cannabinol) cream or vehicle cream as a control. Results from this Phase 2 study of INM-755 CBN cream are expected to be released early calendar Q3 2023. “Enrollment completion of this Phase 2 clinical trial of a cannabinol formulation represents an important milestone for InMed and the scientific community studying rare cannabinoids,” said Eric A. Adams, InMed’s President and CEO. “As a class of compounds, we believe cannabinoids hold tremendous therapeutic potential for their innate interaction with the body, however, to date there have been limited evidence-based studies investigating their effects. Taking a rare cannabinoid formulation through several Ph 1 and Ph 2 clinical trials has been a major undertaking. We look forward to the data read-out in the summer, so we can evaluate our strategic options and next steps.”


Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury, closed at $.8698, +19.15% over the last 5-days after hitting $1.02 during intraday trading on Friday.

On May 15, Atossa announced financial results for the fiscal quarter ended March 31, 2023, and provides an update on recent company development. The highlighted the following: two Phase 2 trials investigating (Z)-endoxifen in neoadjuvant setting initiated and are enrolling patients, Full enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023, & they ended first quarter 2023 with $103.9 million of cash and cash equivalents and no debt.


Atossa’s CEO, Steven Quay, M.D., Ph.D., presented at a Tribe Public even titled “Atossa Therapeutics (NASDAQ: ATOS) Redefining Breast Cancer Prevention and Treatment” on Thursday, May 4, 2023. Dr. Quay provided an update on the clinical development of Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, which is currently being investigated in three separate Phase 2 studies. You may view the event at the following link at the Tribe Public YouTube Channel. .


  • On March 22, Atossa announced financial results for the fiscal quarter and fiscal year ended December 31, 2022 and provided an update on recent company developments. Key developments from Q4 2022 and year to date included the Initiation and First Patient Dosed in Phase 2 EVANGELINE Study – EVANGELINE (Endoxifen Versus exemestANe GosEreLIn), is our Phase 2 randomized non-inferiority study of (Z)-endoxifen compared to exemestane plus goserelin as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 ER+ / HER2- breast cancer. Participants receive neoadjuvant treatment for up to six months, followed by surgery. Several FDA-approved neoadjuvant therapies exist for ER- breast cancers, but few exist for ER+ patients, which account for approximately 78% of breast cancers. We expect to enroll approximately 175 patients at up to 25 sites across the United States. READ MORE.

 

    • On May 16, Chinook announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chronic kidney disease with significant unmet medical need. The companies will leverage Chinook’s precision medicine approach and deep expertise in nephrology and Ionis’ extensive expertise in RNA-targeted therapeutics.

    • On April 13, Chinook announced the appointment of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to Chinook. “We are thrilled to welcome Bob to Chinook’s board of directors as we advance our pipeline through key milestones in 2023 and beyond,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. “Bob brings significant industry experience in building and growing companies and commercially launching new therapies, including in nephrology. His strategic counsel will be invaluable as we continue to advance treatments for patients with rare, severe chronic kidney diseases.” Mr. Azelby has more than two decades of experience leading biotech companies through key periods of development. Most recently, he served as president and chief executive officer of Eliem Therapeutics, a biotechnology company focused on developing novel therapies for neurology disorders, where he led the company through early growth with a $190 million in financing and a successful IPO. Previously, he served as the president and chief executive officer and a member of the board of directors of Alder BioPharmaceuticals, Inc. where he negotiated the successful sale of the company to Lundbeck. Prior to that, Mr. Azelby served as executive vice president and chief commercial officer of Juno Therapeutics through its acquisition by Celgene, and spent 15 years at Amgen in commercial roles across their nephrology and oncology business units. Mr. Azelby currently serves on the board of Clovis Oncology. He holds an M.B.A. from Harvard Business School and a B.A. in Economics and Religious Studies from the University of Virginia.

    • On March 23, Chinook announced presentations at the ISN World Congress of Nephrology 2023 from March 30 – April 2, 2023 in Bangkok, Thailand.



Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK™ bispecific antibody platforms. The company is developing three types of iNK cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia’s proprietary Flex-NK™ technology. These two technology platforms are being used to develop treatment for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Headquartered in Aventura, FL., Cytovia has research and development laboratories in Natick, MA. The company’s own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF). Cytovia has a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities in Greater China.

On May 17, Cytovia Therapeutics R&D Team Presented Poster at ASGCT 2023 on GPC3-Targeted TALEN® Gene-Edited CAR-iNK Cell.

On Dec. 9, 2022, Cytovia announced new preclinical data for its CD38-targeted Flex-NK™ bispecific antibody at the American Society of Hematology’s 64th Annual Meeting (ASH 2022) taking place in New Orleans, LA, and virtually December 10-13th, 2022. “We’re delighted to see further progress on our CD38-targeted Flex-NK™ bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023,” commented Cytovia CEO Dr. Daniel Teper. “The data presented at ASH suggests that CYT-338, our CD38-targeted Flex-NK™ Bispecific Antibody, has a differentiated profile compared to daratumumab, the leading CD38-targeted monoclonal antibody and that CYT-338 may have the ability to overcome NK cell exhaustion and dysfunction.”  Cytovia believes that by redirecting and activating NK cells to kill myeloma cells, bispecific antibodies have the potential to offer new options for patients not responding to first lines of treatment.”


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again this year!

Investing & Inspiration

  1. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
  2. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
  3. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
  4. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
  5. “Action is the foundational key to all success.” – Pablo Picasso
  6. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
  7. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
  8. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
  9. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
  10. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
  11. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
  12. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
  13. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
  14. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
  15. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
  16. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  17. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
  18. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
  19. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
  20. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
  21. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
  22. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  23. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  24. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
  25. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
  26. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  27. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  28. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  29. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  30. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  31. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  32. “I want to put a ding in the universe.” – Steve Jobs

  33. “Research is creating new knowledge.” – Neil Armstrong

  34. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  35. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  36. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey

  37. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  38. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger

  39. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  40. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  41. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain

  42. “The best way out is always through.” – Robert Frost

  43. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi

  44. “Without labor nothing prospers.” – Sophocles

  45. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein

  46. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  47. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  48. “He who is brave is free.” – Lucius Annaeus Seneca

  49. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  50. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  51. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  52. “He who knows that enough is enough will always have enough.” – Lao Tzu

  53. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall

  54. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  55. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  56. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  57. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  58. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  59. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  60. “Success is dependent on effort.” – Sophocles
  61. “Nobody who ever gave his best regretted it.” – George Halas
  62. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  63. “And when I breathed, my breath was lightning.” – Black Elk
  64. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  65. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  66. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  67. “We are an impossibility in an impossible universe.” – Ray Bradbury
  68. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  69. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  70. “Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  71. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  72. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  73. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  74. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  75. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  76. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  77. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  78. “There is more to life than increasing its speed.” – Mahatma Gandhi
  79. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  80. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  81. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  82. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  83. “Life is too short for long-term grudges.” – Elon Musk
  84. “There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  85. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  86. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  87. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  88. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  89. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  90. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  91. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  92. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  93. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  94. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  95. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  96. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  97. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  98. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  99. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  100. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  101. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  102. “Delete the negative; accentuate the positive!” – Donna Karan
  103. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  104. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  105. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  106. “Everything has beauty, but not everyone sees it.” – Confucius
  107. “A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  108. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  109. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  110. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  111. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  112. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  113. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  114. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  115. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  116. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  117. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  118. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  119. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  120. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  121. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  122. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  123. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  124. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  125. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  126. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  127. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  128. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  129. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  130. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  131. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  132. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  133. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  134. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  135. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  136. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  137. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  138. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  139. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  140. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  141. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  142. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  143. “The secret of getting ahead is getting started.” – Mark Twain
  144. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe

Videos



Post View Count : 501

Stay Informed. Stay Competitive.

Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.

We value your privacy and will never share your information.

Recent Posts

VP Watchlist

Trending Posts